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VeteransBackground:Diabetesmellitus (DM), ametabolic disease, is characterized by impaired fasting glucose levels. Type
2 DM is adult onset diabetes. Long non-coding RNAs (lncRNAs) regulate gene expression and multiple studies
have linked lncRNAs to human diseases.
Methods: Serum samples obtained from 96 participating veterans at JAH VA were deposited in the Research
Biospecimen Repository. We used a two-stage strategy to identify an lncRNA whose levels correlated with
T2DM. Initially we screened ﬁve serum samples from diabetic and non-diabetic individuals using lncRNA arrays.
Next, GAS5 lncRNA levelswere analyzed in 96 serum samples using quantitative PCR. Receiver operating charac-
teristic (ROC) analysis was performed to determine the optimal cutoff GAS5 for diagnosis of DM.
Results:Our results demonstrate that decreasedGAS5 levels in serumwere associatedwith diabetes in a cohort of
US military veterans. The ROC analysis revealed an optimal cutoff GAS5 value of less than or equal to 10. qPCR
results indicated that individuals with absolute GAS5 b 10 ng/μl have almost twelve times higher odds of having
diabetes (Exact Odds Ratio [OR] = 11.79 (95% CI: 3.97, 37.26), p b 0.001). Analysis indicated area under curve
(AUC) of ROC of 0.81 with 85.1% sensitivity and 67.3% speciﬁcity in distinguishing non-diabetic from diabetic
subjects. The positive predictive value is 71.4%.
Conclusion: lncRNA GAS5 levels are correlated to prevalence of T2DM.
General Signiﬁcance: Assessment of GAS5 in serum along with other parameters offers greater accuracy in iden-
tifying individuals at-risk for diabetes.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus (DM) comprises of a group of metabolic diseases
characterized by impaired fasting glucose levels. Type 1 DM is juvenile
onset diabetes in which the body does not produce insulin (insulin-
dependent). Type 2 DM is more prevalent with 90% of adult cases
being T2DM. T2DM may be insulin-sensitive or insulin-resistant. The
pathogenesis of diabetes has been studied for several decades; however
additional genetic and environmental factors interact to contribute
towards this epidemic. Risk factors include BMI, smoking, family history,
lifestyle and diet. There is overwhelming evidence linking obesity
and diabetes [1–4]. Within the obese population, patients showoncoding RNA; GAS5, growth-
aracteristics; AUC, area under
D, nonsense mediated decay.
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uted to differences in oxidative stress and AMPK aswell as inﬂammato-
ry cytokines and SIRT1 in the adipose tissue of insulin-resistant subjects
[5]. It is also known that some T2DM patients are lean. These epidemi-
ological studies point to underlying genetic variations which may lead
to onset of T2DM along with the known risk factors.
Long noncoding (lnc) RNAs have varied functions including signal-
ing, molecular decoys, scaffolding and guiding ribonucleoprotein com-
plexes. Multiple lines of evidence link regulatory lncRNAs to human
diseases[6–8]. Sequencing of human genome determined that noncod-
ing RNA accounts for 98% of the transcriptional output of the genome
[9]. Noncoding RNAs are subdivided into transcription RNAs (rRNA
and tRNA), long noncoding RNAs and short noncoding RNAs (miRNA,
siRNA, snoRNA, snRNA). lncRNAs are N200 nt in length and have dis-
tinct structural and spatial features which allow it to bind to DNA,
RNA or protein partners. Most studies were done in cancer cells where
genome-wide association studies (GWAS) indicated that lncRNAs
are important orchestrators of essential biological networks. LncRNAs
are implicated in regulation of genes in cell growth and apoptosis,ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lncRNAs are transcribed by all cell types however their expression levels
are speciﬁc to the cell type. This provides a high degree of speciﬁcity for
its target and mode of action in the biological system.
The lncRNAgrowth-arrest speciﬁc transcript 5 (GAS5) is a 5′-terminal
oligopyrimidine class of genes which regulates cell growth, proliferation
and survival [9,10]. The biogenesis of GAS5 is established. GAS5
gene transcribes several snoRNAs as well as four splice variants of GAS5
mRNA. However, due to the presence of STOP codon, none of the tran-
scripts are transcribed into protein and degrade via the nonsense-
mediated decay (NMD) pathway when translation is initiated. The RNA
levels of GAS5 are regulated by its degradation instead of regulation at
its transcriptional level [11]. GAS5 is encoded at 1q25, a locus displaying
abnormalities in a number of cancers such as melanoma, prostate cancer
and SLE [12,13]. GAS5 inhibits actions of rapamycin which is an mTOR
inhibitor and this affects both leukemic and untransformed human
T-lymphocytes [11]. It is down-regulated in breast cancer [15]. GAS5
acts as a riborepressor by repressing transcription of glucocorticoid
receptor [16]. However, the role of GAS5 lncRNA in diabetes is not
known. Here, we established a correlation of expression levels of the
lncRNA GAS5 detected in serum to T2DM patients.
2. Methods
2.1. Study population
Informed consent was obtained from veterans receiving care
at James A Haley Veterans Hospital, Tampa, FL under IRB approved
study (#Pro00012108). Serum samples are stored in the research bio-
specimen repository (RBR). The de-identiﬁed and coded samples were
provided to the PI along with research parameters such as age, gender,
BMI (calculated as weight in kilograms/height in meter2), diabetic
(determined as glucose levels N125 mg/dL; HbA1c N6.5%) or non-
diabetic (determined as glucose levels b100 mg/dL; HbA1c b6.4%). To
achieve statistical signiﬁcance, serum samples from Caucasian male
volunteers were used as they formed the predominant population
volunteering their serum samples at the JAHVA at the time of initiation
of this study. In addition, patients diagnosed with any form of cancer
were not part of the study group. For this investigative study, 96
serum samples were analyzed (see Table 1).
2.2. Quantitative Real-Time RT-PCR
Total RNA was isolated from serum samples from diabetic or non-
diabetic subjects using TRIzol LS according to themanufacturer's proto-
col (Ambion). For the array, cDNA was prepared from 1.5 μg total RNA
using lncRNA Proﬁler array kit (System Biosciences, cat # RA900A-1)
according to manufacturer's instructions. Ampliﬁcation was performed
with 2X Maxima SYBR Green Masterwith ROX (Thermo Scientiﬁc) and
data were analyzed using System Biosciences software to generate
ΔΔCt values and calculate fold change. U6 snRNA was used as control
to normalize calculations.
For GAS5 real time qPCR, 2 μg RNA was reverse-transcribed using
Qiagen's RT kit. 2 μL of cDNA was ampliﬁed by real-time quantitative
PCR using Syber (SYBR) Green on the ViiaA 7 system (Applied Bio-
systems) to quantify the absolute levels of the transcripts in the samples.
GAPDH was used as the endogenous control. The primers used are:
GAS5 sense primer 5ʹ- AGCTGGAAGTTGAAATGG -3ʹ and anti-sense 5′-
Table 1
Characteristics of patients in this study.
Non diabetic (n = 49) Diabetic (n = 47) P-value
BMI 29.4 ± 6.6 34.8 ± 7.0 b0.001
Age 66.9 ± 9.7 70.3 ± 9.1 0.09
Blood glucose 102.8 ± 16.3 163.6 ± 61.3 b0.001CAAGCCGACTCTCCATACC -3ʹ; GAPDH sense primer 5ʹ- TGACGTGCCG
CCTGGAGAAAC -3ʹ and anti-sense 5ʹ- CCGGCATCGAAGGTGGAAGAG -3ʹ.
These primers were initially tested using cDNA and conditioned media
from human preadipocytes in a RT-PCR reaction using Taq polymerase
to give distinct products corresponding to the respective transcripts.
Next, the optimal primer concentration was determined from a range
of 50–900 nM for forward and reverse primers. The ﬁnal concentration
of 600/600 nMwas selected to ensure efﬁciency and speciﬁcity for its tar-
get based on the dissociation curve that showed a single, sharp peak, in-
dicating that the primers amplify one speciﬁc target. For absolute
quantiﬁcation, a standard curve was generated for each gene in every
assay. To do so, 100–0.4 ng of GAS5 plasmid was used to obtain a stan-
dard curve correlating the amounts with the threshold cycle number
(Ct values). A linear relationship (r2 N 0.96) was obtained for GAS5 and
GAPDH. Real-time PCR was then performed on samples and standards
in triplicate. The plate setup also included a standard series, no template
control, no RNA control, no reverse transcriptase control, and no ampliﬁ-
cation control. The dissociation curve was analyzed for each sample. Ab-
solute quantiﬁcation of GAS5 expression levels for individual samples
was calculated by normalizing the values to GAPDH. The results
were analyzed as described below. A level of p b 0.05 was considered
statistically signiﬁcant. Signiﬁcance was determined after three or
more experiments.
2.3. Statistical analysis
Statistical analyses including sensitivity, speciﬁcity, positive predictive
value, negative predictive value, likelihood ratios and area under the re-
ceiver operating curve analysis were performed using Stata, version
13.1 (Stata Statistical Software: Release 13. College Station, TX: StataCorp
LP). The optimal cutoff point was calculated using the Cutoff Finder [12].
3. Results
3.1. Expression of GAS5 lncRNA in serum
For phase I of our study we screened serum from ﬁve diabetic and
non-diabetic subjects for their long noncoding RNA (lncRNA) proﬁles.
Total RNA was isolated and proﬁles of long non-coding RNAs were
evaluated. To do so, human LncProﬁler (SABiosciences) array compris-
ing of 84 lncRNAs with rigorous controls was used. We observed H19,
HOTAIR, GAS5, ncR-uPAR, EGOb, antiPEG11 and lincRNA-21 expression
in serum from these patients. Other lncRNAs on the array were
undetected for Ct analysis. Amongst the detected lncRNAs in ourFig. 1. LncRNA proﬁler array was used to determine expression of lncRNAs in serum from
diabetic (n=5) andnon-diabetic (n=5) samples. RNAwas extracted fromserumsamples,
reverse transcribed and cDNA used in lncRNA Proﬁler (SBI). Average Ct was calculated for
diabetic and non-diabetic samples, values normalized to hoU6 snRNA. Log graph shows
fold change calculated as 2^ − (Ct(avDM) − Ct(avNDM) × ΔCt(geo mean)). Analysis was
performed by software from SBI.
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samples compared to non-diabetic (Fig. 1). These results showed
that lncRNA GAS5 was present in circulation in serum and its levels
were signiﬁcantly lower (p b 0.0001 using unpaired t-test, PRISM™
software) in diabetic patients compared to non-diabetic samples. Ex-
pression of lncRNAs H19, HOTAIR, lincRNA-p21 whichwere reported
by other studies to be associated with diabetes did not change signif-
icantly between the serum proﬁles of diabetic vs non-diabetic
samples.Fig. 2. (a) Serum from non-diabetic (n= 49) and diabetic (n= 47)were analyzed for expressio
Samples were normalized to U6snRNA. Graph shows absolute quantiﬁcation of GAS5 (ng/μl)
status. The conﬁdence limits are mean ± 2 ∗ standard error.3.2. Analysis of serum samples
Next, we sought to evaluate circulating GAS5 levels in serum from
non-diabetic and diabetic patients. Ninety six serum samples were ob-
tained from Research Bio-specimen Repository (RBR) at the James A.
Haley Veterans' Hospital. To obtain statistically signiﬁcant data,male Cau-
casian patients were selected from the volunteer serum sample pool.
Table 1 shows demographics of the patients (IRB approved protocol
#Pro00012108). The prevalence of DM was 49% (95%CI: 39%, 59.4%).n of GAS5 using qPCR. A standard curve was generated using 100–0.4 ng/μl GAS5 plasmid.
vs HbA1c. (b) Plot of mean (95% conﬁdence interval) GAS5 and HbA1c levels by diabetic
105G. Carter et al. / BBA Clinical 4 (2015) 102–107RNAwas isolated and SYBR Green quantitative PCR in triplicate was
used to obtain absolute GAS5 levels. Our results show that GAS5 levels
were signiﬁcantly decreased in diabetic samples. Markedly, GAS5 levels
were decreased in patients with HbA1c N 5.9; these patients were not
diagnosed as diabetic (cutoff HbA1c N 6.5) in clinic (Figs. 2a, b).
A receiver operating characteristic (ROC) curve was generated for
statistical analysis of GAS5 levels in these 96 samples. ROC is widely
used to investigate a reasonable cutoff level of the target. The ROC
curve displays the relationship of sensitivity and speciﬁcity for GAS5.
ROC analysis of GAS5 revealed the area under curve (AUC) of 0.81
(95% Conﬁdence Interval (CI): 0.72, 0.90) (Fig. 3). The optimal cutoff
GAS5 was less than or equal to 10 ng/μl measured as absolute quantiﬁ-
cation by qPCR, and this value had the sensitivity of 85.1% (95% CI:
72.3%, 92.6%), speciﬁcity of 67.3% (95% CI: 53.4%, 78.8%), positive predic-
tive value (PPV) of 71.4% (95% CI:57.8%, 82.7%), negative predictive
value of 82.5% (95% CI: 67.2%, 92.7%), positive likelihood ratio test 2.61
(95% CI: 1.71, 3.96) and negative likelihood ratio test 0.22 (95% CI:
0.11, 0.45).
Our results indicated that individuals with absolute GAS5 b 10 ng/μl
have nearly twelve times the odds of having diabetes (Odds Ratio
[OR] = 11.79 (95% CI: 3.97, 37.26), p b 0.001). In clinic, individuals
were classiﬁed as diabetic or non-diabetic based on their fasting glucose
or HbA1c levels. The waterfall plot (Fig. 4) shows the classiﬁcation
accuracy of the optimal cutoff point for all 96 patients, as well as the
overall odds ratio for GAS5 as a predictor of diabetes (OR = 0.75 (95%
CI: 0.64, 0.87), p b 0.001). When adjusted for patient BMI, age and
blood glucose, the OR for GAS5 remained signiﬁcant (OR = 0.80 (95%
CI: 0.65–0.97; p = 0.025)).The analysis indicates taking GAS5 levels
are correlated to prevalence of diabetes.
4. Discussion
Diabetes mellitus is a complex disease. There are several approaches
and drugs available to manage the disease. However, little is known
about genomic input on susceptibility and prevention. In 2012, it was
estimated that diabetes costs the nation $245 billion, a 41% increase
from costs incurred in 2007 (ADA study “Economic Costs of Diabetes
in the US in 2012”). Further, 79 million people within USA have pre-
diabetes and 1 in 4 individuals have un-diagnosed state of diabetes
(CDCs 2011 Diabetes fact sheet). 25% of the veterans receiving care at
VA hospitals have diabetes (Veterans' Health Administration data,
2014). In addition, the veteran population has 3.8% higher prevalenceFig. 3. Receiver operating curve (ROC)was performed on GAS5 levels in serum from diabetic pa
Area under curve (AUC) for GAS5 is 0.81 (95% CI: 0.72, 0.90); Sensitivity of 85.1% (95% CI: 72.3%
(95% CI:57.8%, 82.7%).of overweight and obesity, which are predominant causes of diabetes
in adults, than the general US population.
This is theﬁrst report of circulating lncRNAGAS5 as signiﬁcantly cor-
related with diabetes. We demonstrate that GAS5 levels are decreased
in serum of diabetic patients. Our results also showed decreased levels
of GAS5 in certain patients with HbA1c levels N5.9% and b6.4%. These
patients are not diagnosed as diabetic in clinic. Our study demonstrates
that individuals with absolute GAS5 levels of less than 10 ng/μl have
almost twelve times higher odds of having diabetes. It is of great impor-
tance to identify a bioﬂuidmolecule that indicates a change inmicroen-
vironment thatmay result in increased potential of developing diabetes.
Presently, diabetes risk assessments include BMI measurements, family
history, lifestyle and diet questionnaires. Impaired fasting glucose is an
indication of advent of diabetes which may be delayed by exercise and
diet. However, no valid or conﬁrmatory test exists that predict diabetes
risk or state of pre-diabetes or explains the inherent individual differ-
ences to develop diabetes in adulthood. Such a non-invasive test in
serumwould enable early detection of at-risk individuals. This determi-
nation could be easily integrated into a primary care setting.
Studies have identiﬁed lncRNA sets in human pancreatic islets
involved in glucose-stimulated insulin secretion [13,14]. Other studies
identiﬁed ANRIL and H19 lncRNAs in the pancreas playing a role in
diabetes [15,16]. HOTAIR lncRNA is expressed in gluteal adipose
tissue[17]. LncRNA NEAT1 regulates splicing duringadipogenesis [18].
Our results showed that only some of the lncRNAs (Fig. 1) were consis-
tently detected in our samples. Amongst those detected, except for
GAS5, these lncRNAs did not change signiﬁcantly between serum from
non-diabetic subjects compared to diabetic subjects. This may be due
to the fact that lncRNAs are often speciﬁc to the cell type. Additionally,
the levels of lncRNAs within cells differ from its secreted levels. Most
of the lncRNAs associated with diabetes are shown in pancreatic beta
cells and are speciﬁc to the cell. Interestingly, GAS5 promotes apoptosis
and is decreased in breast and prostate cancer cells where survival of
tumors is the underlying function attributed to GAS5 [19–22]. As men-
tioned in our subject demographics, patients with cancer were not
included in this cohort of veterans. These examples further add to our
knowledge of lncRNAs in that most lncRNAs including GAS5 are
multi-faceted and its function and speciﬁcity are often dictated by the
cell type. Secreted lncRNAs are encapsulated within microvescicles or
exosomes and are protected from degradation by RNAses in the blood
[23]. This is the ﬁrst study to our knowledge that identiﬁes and corre-
lates level of circulating lncRNA GAS5 with T2DM. Serum and plasmatients (n= 47) and non-diabetic patients (n= 49) to determine the optimal cutoff values.
, 92.6%), speciﬁcity of 67.3% (95% CI: 53.4%, 78.8%), positive predictive value PPV= 71.4%
Fig. 4. Thewaterfall plot shows the classiﬁcation accuracy of the optimal cutoff point for all 96 patients (diabetic (n= 47)+ non-diabetic (n= 49)= 96), aswell as the overall odds ratio
for GAS5 as a predictor of diabetes (OR = 0.75 (95%CI: 0.64, 0.87), p b 0.001).
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circulating biomarkers for cancer [24–27].
Ourmechanistic studies are currently ongoing to decipher the role of
GAS5 in onset of diabetes and its target gene. This clinical study lays the
foundation towards deciphering themolecularmechanisms and genetic
inﬂuences underlying the pathology of diabetes mellitus. Since lncRNAs
are important regulators of gene expression, it will be interesting to
identify the gene targets of GAS5 that inﬂuence diabetes. Interestingly,
in the breast cancer studies, inhibitors of mTOR were used to increase
GAS5 levels [20]; however inhibition of mTOR also interferes with car-
bohydrate metabolism and increases likelihood of developing diabetes
[28–30]. Additional studies are required to delineate the role of GAS5
in diabetes.
We have undertaken a longitudinal study in collaboration with the
RBR at JAH Veterans Hospital. This study will address the limitations
of the current study such as state of insulin resistance and metabolic
syndrome, equal representation of males and females, effects of over-
weight and morbid obesity, age differences as well as racial and ethnic
differences. Patients with diagnosed state of cancer were not part of
the study as it is documented that circulating lncRNA proﬁles are dys-
regulated in cancer.
In conclusion,we identiﬁed lncRNAGAS5 as a signiﬁcant indicator of
diabetes which can be easily measured in serum in a cohort of US mili-
tary veterans. This study can be expanded to verify themodel that GAS5
levels may predict onset of diabetes in adults. The design may be easily
adapted to high throughput screening of samples in a diagnostic setting
and further reﬁning of diagnosis and prediction of T2DM can be
achieved by combining GAS5 levels with other molecular markers
of DM.
Transparency document
The Transparency document associated with this article can be
found in online version.
Acknowledgments
This work was supported by the Department of Veterans Affairs
Medical Research grant (N.A.P.) (Grant # 821-MR-EN-20606). The con-
tents do not represent the views of the Department of Veterans Affairs
or the United States Government. Research Bio-specimen Repository
(RBR) is supported by the James A. Haley Veterans Hospital, Tampa, FL.References
[1] A.D. Colosia, R. Palencia, S. Khan, Prevalence of hypertension and obesity in patients
with type 2 diabetesmellitus in observational studies: a systematic literature review,
Diabetes Metab. Syndr. Obes. Targets Ther. 6 (2013) 327–338, http://dx.doi.org/10.
2147/DMSO.S51325 Epub 2013/10/02, PubMed PMID: 24082791; PubMed Central
PMCID: PMC3785394.
[2] S.M. Raj, P. Halebeedu, J.S. Kadandale, M.M. Lahr, I.G. Romero, J.R. Yadhav, M. Iliescu,
N. Rai, F. Crivellaro, G. Chaubey, R. Villems, K. Thangaraj, K. Muniyappa, H.S.
Chandra, T. Kivisild, Variation at diabetes- and obesity-associated loci may mirror
neutral patterns of human population diversity and diabetes prevalence in India,
Ann. Hum. Genet. (2013)http://dx.doi.org/10.1111/ahg.12028 Epub 2013/07/03,
PubMed PMID: 23808542.
[3] G. Sundborn, P.A. Metcalf, D. Gentles, R. Scragg, L. Dyall, P. Black, R. Jackson, Over-
weight and obesity prevalence among adult Paciﬁc peoples and Europeans in the
Diabetes Heart and Health Study (DHAHS) 2002–2003, Auckland New Zealand, N.
Z. Med. J. 123 (1311) (2010) 30–42 Epub 2010/04/03, PubMed PMID: 20360794.
[4] A.G. Crawford, C. Cote, J. Couto, M. Daskiran, C. Gunnarsson, K. Haas, S. Haas, S.C.
Nigam, R. Schuette, Prevalence of obesity, type II diabetes mellitus, hyperlipidemia,
and hypertension in the United States: ﬁndings from the GE Centricity Electronic
Medical Record database, Popul. Health Manag. 13 (3) (2010) 151–161, http://dx.
doi.org/10.1089/pop.2009.0039 Epub 2010/06/05, PubMed PMID: 20521902.
[5] X.J. Xu, W.J. Pories, L.G. Dohm, N.B. Ruderman, What distinguishes adipose tissue of
severely obese humans who are insulin sensitive and resistant? Curr. Opin. Lipidol.
24 (1) (2013) 49–56, http://dx.doi.org/10.1097/MOL.0b013e32835b465b Epub
2013/01/10, PubMed PMID: 23298959; PubMed Central PMCID: PMC3575680.
[6] X. Chen, G.Y. Yan, Novel human lncRNA-disease association inference based on
lncRNA expression proﬁles, Bioinformatics 29 (20) (2013) 2617–2624, http://dx.
doi.org/10.1093/bioinformatics/btt426 PubMed PMID: 24002109.
[7] M. Arase, K. Horiguchi, S. Ehata, M. Morikawa, S. Tsutsumi, H. Aburatani, K.
Miyazono, D. Koinuma, Transforming growth factor-beta-induced lncRNA-Smad7
inhibits apoptosis of mouse breast cancer JygMC(A) cells, Cancer Sci. 105 (8)
(2014) 974–982, http://dx.doi.org/10.1111/cas.12454 PubMed PMID: 24863656.
[8] Q. Liu, J. Huang, N. Zhou, Z. Zhang, A. Zhang, Z. Lu, F.Wu, Y.Y. Mo, LncRNA loc285194
is a p53-regulated tumor suppressor, Nucleic Acids Res. 41 (9) (2013) 4976–4987,
http://dx.doi.org/10.1093/nar/gkt182 PubMed PMID: 23558749; PubMed Central
PMCID: PMC3643595.
[9] E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K. Devon, K.
Dewar, M. Doyle, W. FitzHugh, R. Funke, D. Gage, K. Harris, A. Heaford, J. Howland,
L. Kann, J. Lehoczky, R. LeVine, P. McEwan, K. McKernan, J. Meldrim, J.P. Mesirov,
C. Miranda, W. Morris, J. Naylor, C. Raymond, M. Rosetti, R. Santos, A. Sheridan, C.
Sougnez, N. Stange-Thomann, N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers,
J. Sulston, R. Ainscough, S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson,
R. Deadman, P. Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham,
S. Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray, L.
Matthews, S. Mercer, S. Milne, J.C. Mullikin, A. Mungall, R. Plumb, M. Ross, R.
Shownkeen, S. Sims, R.H. Waterston, R.K. Wilson, L.W. Hillier, M.P. JD, M.A. Marra,
E.R. Mardis, L.A. Fulton, A.T. Chinwalla, K.H. Pepin, W.R. Gish, S.L. Chissoe, M.C.
Wendl, K.D. Delehaunty, T.L. Miner, A. Delehaunty, J.B. Kramer, L.L. Cook, R.S.
Fulton, D.L. Johnson, P.J. Minx, S.W. Clifton, T. Hawkins, E. Branscomb, P. Predki, P.
Richardson, S. Wenning, T. Slezak, N. Doggett, J.F. Cheng, A. Olsen, S. Lucas, C.
Elkin, E. Uberbacher, M. Frazier, R.A. Gibbs, D.M. Muzny, S.E. Scherer, J.B. Bouck,
E.J. Sodergren, K.C. Worley, C.M. Rives, J.H. Gorrell, M.L. Metzker, S.L. Naylor, R.S.
Kucherlapati, D.L. Nelson, G.M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, T.
Yada, A. Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J.
Weissenbach, R. Heilig, W. Saurin, F. Artiguenave, P. Brottier, T. Bruls, E. Pelletier,
107G. Carter et al. / BBA Clinical 4 (2015) 102–107C. Robert, P. Wincker, D.R. Smith, L. Doucette-Stamm, M. Rubenﬁeld, K. Weinstock,
H.M. Lee, J. Dubois, A. Rosenthal, M. Platzer, G. Nyakatura, S. Taudien, A. Rump, H.
Yang, J. Yu, J. Wang, G. Huang, J. Gu, L. Hood, L. Rowen, A. Madan, S. Qin, R.W.
Davis, N.A. Federspiel, A.P. Abola, M.J. Proctor, R.M. Myers, J. Schmutz, M. Dickson,
J. Grimwood, D.R. Cox, M.V. Olson, R. Kaul, C. Raymond, N. Shimizu, K. Kawasaki,
S. Minoshima, G.A. Evans, M. Athanasiou, R. Schultz, B.A. Roe, F. Chen, H. Pan, J.
Ramser, H. Lehrach, R. Reinhardt, M.C. WR, M. de la Bastide, N. Dedhia, H. Blocker,
K. Hornischer, G. Nordsiek, R. Agarwala, L. Aravind, J.A. Bailey, A. Bateman, S.
Batzoglou, E. Birney, P. Bork, D.G. Brown, C.B. Burge, L. Cerutti, H.C. Chen, D.
Church, M. Clamp, R.R. Copley, T. Doerks, S.R. Eddy, E.E. Eichler, T.S. Furey, J.
Galagan, J.G. Gilbert, C. Harmon, Y. Hayashizaki, D. Haussler, H. Hermjakob, K.
Hokamp, W. Jang, L.S. Johnson, T.A. Jones, S. Kasif, A. Kaspryzk, S. Kennedy, W.J.
Kent, P. Kitts, E.V. Koonin, I. Korf, D. Kulp, D. Lancet, T.M. Lowe, A. McLysaght, T.
Mikkelsen, J.V. Moran, N. Mulder, V.J. Pollara, C.P. Ponting, G. Schuler, J. Schultz, G.
Slater, A.F. Smit, E. Stupka, J. Szustakowski, D. Thierry-Mieg, J. Thierry-Mieg, L.
Wagner, J. Wallis, R. Wheeler, A. Williams, Y.I. Wolf, K.H. Wolfe, S.P. Yang, R.F.
Yeh, F. Collins, M.S. Guyer, J. Peterson, A. Felsenfeld, K.A. Wetterstrand, A. Patrinos,
M.J. Morgan, P. de Jong, J.J. Catanese, K. Osoegawa, H. Shizuya, S. Choi, Y.J. Chen,
International human genome sequencing C. Initial sequencing and analysis of the
human genome, Nature 409 (6822) (2001) 860–921, http://dx.doi.org/10.1038/
35057062 PubMed PMID: 11237011.
[10] P.P. Amaral,M.B. Clark, D.K. Gascoigne,M.E. Dinger, J.S.Mattick, lncRNAdb: a reference
database for long noncoding RNAs, Nucleic Acids Res. 39 (2011)http://dx.doi.org/10.
1093/nar/gkq1138 (Database issue):D146-51. Epub 2010/11/30, PubMed PMID:
21112873; PubMed Central PMCID: PMC3013714.
[11] G.T. Williams, M. Mourtada-Maarabouni, F. Farzaneh, A critical role for non-coding
RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes,
Biochem. Soc. Trans. 39 (2) (2011) 482–486, http://dx.doi.org/10.1042/
BST0390482 Epub 2011/03/25, PubMed PMID: 21428924.
[12] J. Budczies, F. Klauschen, B.V. Sinn, B. Gyorffy, W.D. Schmitt, S. Darb-Esfahani, C.
Denkert, Cutoff ﬁnder: a comprehensive and straightforward Web application en-
abling rapid biomarker cutoff optimization, PLoS One 7 (12) (2012;) e51862,
http://dx.doi.org/10.1371/journal.pone.0051862 PubMed PMID: 23251644;
PubMed Central PMCID: PMC3522617.
[13] J. Taneera, J. Fadista, E. Ahlqvist, D. Atac, E. Ottosson-Laakso, C.B. Wollheim, L. Groop,
Identiﬁcation of novel genes for glucose metabolism based upon expression pattern
in human islets and effect on insulin secretion and glycemia, Hum. Mol. Genet. 24
(7) (2015) 1945–1955, http://dx.doi.org/10.1093/hmg/ddu610 PubMed PMID:
25489054.
[14] J. Fadista, P. Vikman, E.O. Laakso, I.G. Mollet, J.L. Esguerra, J. Taneera, P. Storm, P.
Osmark, C. Ladenvall, R.B. Prasad, K.B. Hansson, F. Finotello, K. Uvebrant, J.K. Ofori, B.
Di Camillo, U. Krus, C.M. Cilio, O. Hansson, L. Eliasson, A.H. Rosengren, E. Renstrom,
C.B.Wollheim, L. Groop,Global genomic and transcriptomic analysis of humanpancre-
atic islets reveals novel genes inﬂuencing glucose metabolism, Proc. Natl. Acad. Sci. U.
S. A. 111 (38) (2014) 13924–13929, http://dx.doi.org/10.1073/pnas.1402665111
PubMed PMID: 25201977; PubMed Central PMCID: PMC4183326.
[15] G.L. Ding, F.F. Wang, J. Shu, S. Tian, Y. Jiang, D. Zhang, N.Wang, Q. Luo, Y. Zhang, F. Jin,
P.C. Leung, J.Z. Sheng, H.F. Huang, Transgenerational glucose intolerance with Igf2/
H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia,
Diabetes 61 (5) (2012) 1133–1142, http://dx.doi.org/10.2337/db11-1314 PubMed
PMID: 22447856; PubMed Central PMCID: PMC3331740.
[16] E. Pasmant, A. Sabbagh, M. Vidaud, I. Bieche, ANRIL, a long, noncoding RNA, is an
unexpected major hotspot in GWAS, FASEB J. 25 (2) (2011) 444–448, http://dx.
doi.org/10.1096/fj.10–172452 PubMed PMID: 20956613.
[17] A. Divoux, K. Karastergiou, H. Xie, W. Guo, R.J. Perera, S.K. Fried, S.R. Smith, Identiﬁ-
cation of a novel lncRNA in gluteal adipose tissue and evidence for its positive effect
on preadipocyte differentiation, Obesity 22 (8) (2014) 1781–1785, http://dx.doi.
org/10.1002/oby.20793 PubMed PMID: 24862299; PubMed Central PMCID:
PMC4228784.[18] D.R. Cooper, G. Carter, P. Li, R. Patel, J.E. Watson, N.A. Patel, Long non-coding RNA
NEAT1 associates with SRp40 to temporally regulate PPARgamma2 splicing during
adipogenesis in 3T3–L1 Cells, Genes 5 (4) (2014) 1050–1063, http://dx.doi.
org/10.3390/genes5041050 PubMed PMID: 25437750; PubMed Central
PMCID: PMC4276926.
[19] K. Yacqub-Usman,M.R. Pickard, G.T. Williams, Reciprocal regulation of GAS5 lncRNA
levels and mTOR inhibitor action in prostate cancer cells, Prostate 75 (7) (2015)
693–705, http://dx.doi.org/10.1002/pros.22952 PubMed PMID: 25650269.
[20] M.R. Pickard, G.T. Williams, Regulation of apoptosis by long non-coding RNA GAS5
in breast cancer cells: implications for chemotherapy. Breast cancer research and
treatment, 145 (2) (2014) 359–370, http://dx.doi.org/10.1007/s10549-014–2974-
y PubMed PMID: 24789445.
[21] M.R. Pickard, M. Mourtada-Maarabouni, G.T. Williams, Long non-coding RNA GAS5
regulates apoptosis in prostate cancer cell lines, Biochim. Biophys. Acta 1832 (10)
(2013) 1613–1623, http://dx.doi.org/10.1016/j.bbadis.2013.05.005 PubMed PMID:
23676682.
[22] M. Mourtada-Maarabouni, M.R. Pickard, V.L. Hedge, F. Farzaneh, G.T. Williams,
GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast
cancer, Oncogene 28 (2) (2009) 195–208, http://dx.doi.org/10.1038/onc.2008.373
PubMed PMID: 18836484.
[23] X. Huang, T. Yuan, M. Tschannen, Z. Sun, H. Jacob, M. Du, M. Liang, R.L. Dittmar, Y.
Liu, M. Liang, M. Kohli, S.N. Thibodeau, L. Boardman, L. Wang, Characterization of
human plasma-derived exosomal RNAs by deep sequencing, BMC Genomics 14
(2013) 319, http://dx.doi.org/10.1186/1471–2164–14–319 PubMed PMID:
23663360; PubMed Central PMCID: PMC3653748.
[24] N.B. Tsui, E.K. Ng, Y.M. Lo, Molecular analysis of circulating RNA in plasma, Methods
Mol. Biol. 336 (2006) 123–134, http://dx.doi.org/10.1385/1–59745–074-X:123
Epub 2006/08/19, PubMed PMID: 16916258.
[25] K. Wang, Y. Yuan, H. Li, J.H. Cho, D. Huang, L. Gray, S. Qin, D.J. Galas, The spectrum of
circulating RNA: a window into systems toxicology, Toxicol. Sci. 132 (2) (2013)
478–492, http://dx.doi.org/10.1093/toxsci/kft014 Epub 2013/01/30, PubMed
PMID: 23358195.
[26] A. Baraniskin, S. Nopel-Dunnebacke, M. Ahrens, S.G. Jensen, H. Zollner, A. Maghnouj,
A. Wos, J. Mayerle, J. Munding, D. Kost, A. Reinacher-Schick, S. Liffers, R. Schroers,
A.M. Chromik, H.E. Meyer, W. Uhl, S. Klein-Scory, F.U. Weiss, C. Stephan, I.
Schwarte-Waldhoff, M.M. Lerch, A. Tannapfel, W. Schmiegel, C.L. Andersen, S.A.
Hahn, Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker
for pancreatic and colorectal adenocarcinoma, Int. J. Cancer 132 (2) (2013)
E48–E57, http://dx.doi.org/10.1002/ijc.27791 Epub 2012/08/22, PubMed PMID:
22907602.
[27] R.E. Payne, F.Wang, N. Su, J. Krell, A. Zebrowski, E. Yague, X.J.Ma, Y. Luo, R.C. Coombes,
Viable circulating tumour cell detection usingmultiplex RNA in situ hybridisation pre-
dicts progression-free survival in metastatic breast cancer patients, Br. J. Cancer 106
(11) (2012) 1790–1797, http://dx.doi.org/10.1038/bjc.2012.137 Epub 2012/04/28,
PubMed PMID: 22538972; PubMed Central PMCID: PMC3364118.
[28] J. Xie, T.P. Herbert, The role of mammalian target of rapamycin (mTOR) in the
regulation of pancreatic beta-cell mass: implications in the development of type-2
diabetes, Cell. Mol. Life Sci. 69 (8) (2012) 1289–1304, http://dx.doi.org/10.1007/
s00018-011–0874–4 PubMed PMID: 22068611.
[29] A. Ost, K. Svensson, I. Ruishalme, C. Brannmark, N. Franck, H. Krook, P. Sandstrom, P.
Kjolhede, P. Stralfors, AttenuatedmTOR signaling and enhanced autophagy in adipo-
cytes from obese patients with type 2 diabetes, Mol. Med. 16 (7–8) (2010) 235–246,
http://dx.doi.org/10.2119/molmed.2010.00023 PubMed PMID: 20386866; PubMed
Central PMCID: PMC2896460.
[30] M. Fraenkel, M. Ketzinel-Gilad, Y. Ariav, O. Pappo, M. Karaca, J. Castel, M.F. Berthault,
C. Magnan, E. Cerasi, N. Kaiser, G. Leibowitz, mTOR inhibition by rapamycin prevents
beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2
diabetes, Diabetes 57 (4) (2008) 945–957, http://dx.doi.org/10.2337/db07-0922
PubMed PMID: 18174523.
